As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...

The Association for Accessible Medicines and its Biosimilars Council have released an analysis undertaken by the IQVIA Institute for Human Data Science on behalf of AAM assessing the impact of patent ...

According to the Association for Accessible Medicine’s 2024 U.S. Generic and Biosimilar Medicines Savings Report, the use of Food and Drug Administration-approved generic and biosimilar medicines ...

Both Alvotech ALVO and Teva Pharmaceuticals TEVA operate in the biosimilar space, but their business models differ significantly. ALVO has built its revenue model around partnerships, relying on ...

Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include novel drugs that offer new treatment options, as well as first generics and ...

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...

In 2024, the use of generic and biosimilar medicines saved $467 billion for the United States health-care system and the patients who use it, according to a recent report by the Association for ...

Living with a chronic illness changes how you see the world. Time is no longer measured in milestones or seasons, but in flares and remissions, blood tests and hospital appointments. Chronic illnesses ...